Skip to Main Content

Paper Details

Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.
Cancer Res Commun
3
2023
Author NameAffiliation
Adam SharpInstitute of Cancer Research
Adam SharpThe Royal Marsden NHS Foundation Trust
  • 1 - 2

Datasets

Release 1.2